Also, the role of both quantitative and qualitative DWI evaluation in HER2-positive breast cancer remains unclear since most studies do not differ between breast cancer subtypes despite the difference in accuracy for identifying residual disease of DCE-MRI [23–26]. This evidence concerns the gene ERBB2 and breast cancer.